Cancer BiologybioRxivPreprint
The MYC axis in advanced prostate cancer is impacted through concurrent targeting of ERβ and AR using a novel ERβ-selective ligand alongside Enzalutamide
Jaimie S. Gray, Sajad A. Wani, Shahid Hussain…·Moray J. Campbell
This study shows that combining a novel ERβ ligand with Enzalutamide reduces MYC signaling and growth in advanced prostate cancer.
4 citations